Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents-Reference-Cited by-同舟云学术

Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents

Published:2017-05-12 Issue:18 Volume:123 Page:3609-3616
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Millot Frédéric¹^ORCID,Dupraz Christelle¹,Guilhot Joelle¹,Suttorp Meinolf²,Brizard Françoise¹,Leblanc Thierry³,Güneş Adalet Meral⁴,Sedlacek Petr⁵,De Bont Evelyne⁶⁷,Li Chi Kong⁸,Kalwak Krzysztof⁹,Lausen Birgitte¹⁰,Culic Srdjana¹¹,Dworzak Michael¹²,Kaiserova Emilia¹³,De Moerloose Barbara¹⁴,Roula Farah¹⁵,Biondi Andrea¹⁶,Baruchel André³,Guilhot François¹

Affiliation:

1. INSERM Clinical Investigation Center 1402; Poitiers University; Poitiers France

2. Department of Pediatrics; Carl Gustav Carus University Hospital; Dresden Germany

3. Department of Pediatric Hematology; Robert Debré Hospital; Paris France

4. Department of Pediatric Hematology; Uludağ University Hospital; Görükle Bursa Turkey

5. Department of Pediatric Hematology-Oncology, Motol University Hospital; Charles University; Prague Czech Republic

6. Department of Pediatric Oncology-Hematology, University Medical Center Groningen; University of Groningen; Groningen the Netherlands

7. Dutch Childhood Oncology Group; the Hague the Netherlands

8. Department of Pediatrics, Prince of Wales Hospital; Chinese University of Hong Kong; Hong Kong China

9. Department of Pediatric Hematology-Oncology and Transplantation; Wroclaw Medical University; Wroclaw Poland

10. Department of Pediatrics, Rigshospitalet; University Hospital; Copenhagen Denmark

11. Department of Pediatric Hematology, Oncology, Immunology, and Medical Genetics; Clinical Hospital; Split Croatia

12. Children's Cancer Research Institute and St. Anna Children's Hospital; Vienna Austria

13. Department of Pediatric Oncology; University Children's Hospital; Bratislava Slovakia

14. Department of Pediatrics; Ghent University Hospital; Ghent Belgium

15. Department of Pediatrics; Saint George Hospital University Medical Centre; Beirut Lebanon

16. Department of Pediatrics, San Gerardo Hospital; University of Milano-Bicocca, Fondazione Monza e Brianza per il Bambino e la sua Mamma; Monza Italy

Funder

Novartis Pharmaceuticals

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference26 articles.

1. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining;Rowley;Nature.,1973

2. Cytogenetics in CML: more important than you think;Guilhot;Blood.,2016

3. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy;Chen;Leukemia.,2016

4. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy;Wang;Blood.,2016

5. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis;Marzocchi;Blood.,2011

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cases of Patients Treated in Countries With Limited Resources and Discussed by Experts of the International CML Foundation (iCMLf)—Case No. 1: A Boy Presenting With Priapism and Loss of Vision;Case Reports in Oncological Medicine;2024-01

2. Patterns of chromosome abnormalities in a sample of Colombian patients with chronic myeloid leukemia;Universitas Scientiarum;2023-12-21

3. Chronic myeloid leukemia (CML) in children and adolescents—Clinicopathological findings;European Journal of Haematology;2023-11-20

4. The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure;Leukemia Research;2023-09

5. Is very high platelet count always associated with essential thrombocythemia? An unusual presentation in a child;Laboratory Medicine;2023-06-23